These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 29110275)

  • 41. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion in Patients with High-Grade, High-Volume Disseminated Mucinous Appendiceal Neoplasms.
    Polanco PM; Ding Y; Knox JM; Ramalingam L; Jones H; Hogg ME; Zureikat AH; Holtzman MP; Pingpank J; Ahrendt S; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2016 Feb; 23(2):382-90. PubMed ID: 26429720
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma.
    Mercier F; Jeremie G; Alyami M; Delphine V; Vahan K; Pascal R; Sylvie I; Guillaume P; Olivier G
    Surg Endosc; 2020 Nov; 34(11):4916-4923. PubMed ID: 31792692
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Appendiceal pseudomyxoma peritonei: predictors of recurrence and iterative surgery.
    Kong JC; Flood MP; Guerra GR; Liesegang A; Wong WJ; Mitchell C; Warrier SK; Naidu S; Meade B; Lutton N; Heriot AG
    Colorectal Dis; 2021 Sep; 23(9):2368-2375. PubMed ID: 34157209
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The modified Glasgow prognosis score predicts for overall and disease-free survival following cytoreductive surgery and HIPEC in patients with pseudomyxoma peritonei of appendiceal origin.
    Tan GH; Novo CA; Dayal S; Chandrakumaran K; Mohamed F; Cecil T; Moran BJ
    Eur J Surg Oncol; 2017 Feb; 43(2):388-394. PubMed ID: 27866811
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Single centre guidelines for radiological follow-up based on 775 patients treated by cytoreductive surgery and HIPEC for appendiceal pseudomyxoma peritonei.
    Govaerts K; Chandrakumaran K; Carr NJ; Cecil TD; Dayal S; Mohamed F; Thrower A; Moran BJ
    Eur J Surg Oncol; 2018 Sep; 44(9):1371-1377. PubMed ID: 30017331
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Progression of peritoneal adenomucinosis to the scrotum: a rare occurrence treated with cytoreductive surgery and hyperthermic chemoperfusion of the scrotum in two patients.
    Sardi A; Jiménez WA; Wosu C
    Colomb Med (Cali); 2014; 45(2):77-80. PubMed ID: 25100893
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Health related quality of life is excellent and sustained at two decades after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in survivors of pseudomyxoma peritonei of appendiceal origin.
    Kung V; Delisle M; Alves S; Mohamed F; Cecil T; Moran B
    Eur J Surg Oncol; 2023 Nov; 49(11):107045. PubMed ID: 37677915
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer.
    Magge D; Ramalingam L; Shuai Y; Edwards RP; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL; Choudry HA
    J Surg Oncol; 2017 Sep; 116(3):320-328. PubMed ID: 28628712
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Mercier F; Dagbert F; Pocard M; Goéré D; Quenet F; Wernert R; Dumont F; Brigand C; Passot G; Glehen O;
    BJS Open; 2019 Apr; 3(2):195-202. PubMed ID: 30957067
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei.
    Sørensen O; Andersen AM; Larsen SG; Giercksky KE; Flatmark K
    Clin Exp Metastasis; 2019 Dec; 36(6):511-518. PubMed ID: 31541325
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases.
    Narasimhan V; Das A; Warrier S; Lynch C; McCormick J; Tie J; Michael M; Ramsay R; Heriot A
    Langenbecks Arch Surg; 2019 Aug; 404(5):527-539. PubMed ID: 31377856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adverse Events Postoperatively Had No Impact on Long-Term Survival of Patients Treated with Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Appendiceal Cancer with Peritoneal Metastases.
    Ihemelandu C; Mavros MN; Sugarbaker P
    Ann Surg Oncol; 2016 Dec; 23(13):4231-4237. PubMed ID: 27338748
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overall Survival is More Closely Associated with Peritoneal than Primary Appendiceal Pathological Grade in Pseudomyxoma Peritonei with Discordant Pathology.
    Memon AA; Godbole C; Cecil T; Dayal S; Moran B; Tzivanakis A; Mohamed F; Carr NJ
    Ann Surg Oncol; 2022 Apr; 29(4):2607-2613. PubMed ID: 34731401
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a single center experience.
    Robella M; Vaira M; Marsanic P; Mellano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2013 Dec; 68(6):569-77. PubMed ID: 24193289
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of an inguinal hernia in patients with pseudomyxoma peritonei.
    Sugarbaker PH
    Eur J Surg Oncol; 2017 Jun; 43(6):1083-1087. PubMed ID: 28131668
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mucinous appendiceal neoplasms: classification, imaging, and HIPEC.
    Bartlett DJ; Thacker PG; Grotz TE; Graham RP; Fletcher JG; VanBuren WM; Iyer VR; Fidler JL; Menias CO; Wasif N; Sheedy SP
    Abdom Radiol (NY); 2019 May; 44(5):1686-1702. PubMed ID: 30610247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Significance of serum tumor marker levels in peritoneal carcinomatosis of appendiceal origin.
    Wagner PL; Austin F; Sathaiah M; Magge D; Maduekwe U; Ramalingam L; Jones HL; Holtzman MP; Ahrendt SA; Zureikat AH; Pingpank JF; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2013 Feb; 20(2):506-14. PubMed ID: 22941175
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early Postoperative Intraperitoneal Chemotherapy for Low-Grade Appendiceal Mucinous Neoplasms with Pseudomyxoma Peritonei: Is it Beneficial?
    Huang Y; Alzahrani NA; Liauw W; Traiki TB; Morris DL
    Ann Surg Oncol; 2017 Jan; 24(1):176-183. PubMed ID: 27718032
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of Mucin Cellularity and Distribution on Survival in Newly Diagnosed Patients with Low-Grade Appendiceal Mucinous Neoplasm Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Nikiforchin A; King MC; Baron E; MacDonald R; Sittig M; Nieroda C; Gushchin V; Sardi A
    Ann Surg Oncol; 2020 Dec; 27(13):4908-4917. PubMed ID: 32409962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.